IQVIA HoldingsLTS:0JDM +0.49%86 Buyback Yield % is 4.13 as of Jul. 07, 2026, which is 29% above its 10-year median of 3.19. GuruFocus rates LTS:0JDM with a GF Score™ of 86/100 and a GF Value™ of $251.07 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 91 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 92.31% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for IQVIA Holdings's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JDM vs WAT, ILMN, NTRA: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (LTS:0JDM) has a Buyback Yield % of 4.13 as of Jul. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on IQVIA Holdings and its competitors. This is 29% above median its historical median of 3.19. Over the past decade, IQVIA Holdings' Buyback Yield % has ranged from 0.44 to 12.86. According to the industry distribution chart, IQVIA Holdings ranks #7 out of 91 companies in the Medical Diagnostics & Research industry, placing it in the top 7.7%.
Is IQVIA Holdings' Buyback Yield % too high?
IQVIA Holdings' current Buyback Yield % of 4.13 is 29% above median its 10-year median of 3.19. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 12.86. Based on the distribution chart, IQVIA Holdings ranks #7 out of 91 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IQVIA Holdings has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Buyback Yield % compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #7 out of 91 companies for Buyback Yield %. This places IQVIA Holdings in the top 8% of its industry — outperforming the majority of peers. Historically, IQVIA Holdings' own Buyback Yield % has ranged from 0.44 to 12.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on IQVIA Holdings and its competitors. IQVIA Holdings's current Buyback Yield % is 4.13, which is 29% above median its own 10-year median of 3.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Modestly Undervalued. The stock's GF Value™ is $251.07, compared to a current price of $207.24 — trading 17.5% below its estimated fair value. The current Buyback Yield % is 4.13, which is 29% above median its 10-year median of 3.19. IQVIA Holdings' overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current Buyback Yield % is 4.13 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of $207.24 is trading 17.5% below its estimated GF Value™ of $251.07.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for LTS:0JDM:
Buyback Yield %: 4.13 (29% above median its 10-year median of 3.19)
GF Value™: $251.07 vs. price of $207.24 (17.5% below fair value)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
86GF Score
Get the complete analysis for LTS:0JDM
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
